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Murine hematopoietic stem cell activity is derived
from pre-circulation embryos but not yolk sacs
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The embryonic site of definitive hematopoietic stem cell (dHSC) origination has been
debated for decades. Although an intra-embryonic origin is well supported, the yolk sac (YS)
contribution to adult hematopoiesis remains controversial. The same developmental origin
makes it difficult to identify specific markers that discern between an intraembryonic versus
YS-origin using a lineage trace approach. Additionally, the highly migratory nature of blood
cells and the inability of pre-circulatory embryonic cells (i.e., 5–7 somite pairs (sp)) to
robustly engraft in transplantation, even after culture, has precluded scientists from properly
answering these questions. Here we report robust, multi-lineage and serially transplantable
dHSC activity from cultured 2–7sp murine embryonic explants (Em-Ex). dHSC are unde-
tectable in 2–7sp YS explants. Additionally, the engraftment from Em-Ex is confined to
an emerging CD31+CD45+c-Kit+CD41− population. In sum, our work supports a model in
which the embryo, not the YS, is the major source of lifelong definitive hematopoiesis.
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The embryonic origin of cells that sustain lifelong mam-malian hematopoiesis and blood production has long beendebated. Resolving this debate is complicated by the
emergence of sequential waves of blood cells at distinct sites
within the embryo:1 blood-islands composed of primitive nucle-
ated erythrocytes first appear at E7-E7.5 in the YS. Definitive
erythroid-myeloid precursors also emerge from the YS at E8.5.
Finally, around E10.5-E11.5, the first definitive HSC (dHSC)
capable of reconstituting the hematopoietic system of adult
recipients using existing assays are detected and presumably
these precursors support lifelong blood production2,3. The site of
origin of these dHSC has been contentious2–16. An intra-
embryonic origin, concentrated around the para-aortic splanch-
nopleura (PSp)-derived aorta-gonad-mesonephros region
(AGM), is currently the favored model. In contrast, the con-
tribution of YS to the dHSC compartment is controversial1. Early
work implicated the YS blood islands as a source of both
primitive-erythroblasts and dHSC;1,4–6,8,15 however later work
challenged this hypothesis. In particular, Dieterlen-Lievre and
colleagues demonstrated an intra-embryonic origin for definitive
hematopoiesis in vertebrates using quail-chick chimeras7,16.
Recent work has formally demonstrated in chicken the presence
of bona fide dHSC originating from the embryo aortas but not
from the YS, allantois or head17. An intra-embryonic origin for
dHSC in mammals was later supported by studies showing that
the first dHSC capable of reconstituting adult recipients are
detected in the PSp/AGM region2,3. Despite these findings, the
potential contribution of YS to lifelong hematopoiesis has not
been completely excluded13,14,18,19.
YS-derived and AGM-derived hematopoietic progenitors both
arise from hemogenic endothelial (HE) precursors that are
mesodermal in origin14,20–25. Very few markers have been
identified that could potentially distinguish between AGM and YS
hematopoietic precursors. The highly migratory nature of blood
cells in circulating embryos and the inability of cells isolated from
pre-circulation embryos to robustly engraft in transplantation
assays, even after ex vivo culture, has precluded definitively
addressing if the YS hemogenic endothelium (YS-HE) contributes
to lifelong hematopoiesis and the adult dHSC pool12,26. PSp tis-
sue from pre-circulation embryos generated long-term multi-
lineage engraftment while YS did not, but reconstitution was
extremely low (1–5%) in these experiments, raising concerns that
lower activity present in the YS would have been very difficult to
detect12. Furthermore, PSp-derived reconstitution was only
observed in severely immunocompromised recipient mice (i.e.,
Rag2γc−/−)12. Indeed, it has recently been suggested that the YS
may be a major embryonic source of dHSC14. Lineage tracing
studies exploiting the high expression of LYVE1 (lymphatic vessel
endothelial hyaluronan receptor-1) in the YS and vitelline-
endothelium concluded that >40% of adult blood may ultimately
derive from these sites in mice14.
Here, we present a platform that supports the ex vivo devel-
opment of robust dHSC activity from pre-circulation embryos,
allowing us to rigorously interrogate the dHSC-forming potential
of both the early embryo and YS. We find that cultured pre-
circulatory Em-Ex, but not YS explants (YS-Ex), yield robust
dHSC activity. Importantly, this activity in cultured Em-Ex was
restricted to an emerging CD31+CD45+c-Kit+CD41− popula-
tion that also develops in cultured YS-Ex. Additionally, in pre-
circulation embryos, we identify LYVE1+CD31+ aortic endo-
thelial cells, confirming that LYVE1 expression is found outside
the YS and vitelline HE at this early stage of development14. We
further demonstrate that pre-circulatory Em-Ex-derived LYVE1+
precursors yield robust dHSC activity, indicating that LYVE1
constitutes an early marker of intraembryonic definitive
hematopoiesis. In sum, our work strongly supports a model
in which the YS is not a major source of lifelong definitive
hematopoiesis.
Results
Robust dHSC activity generation from pre-circulatory
embryos. Blood circulation is established around 5–7sp (≈E8.5).
The first heartbeat is detected at 5sp, a consistent blood flow
begins around 7sp and fully functional circulation is established
after E10, as evidenced by the uneven distribution of erythroblasts
within the embryo vasculature prior to 35sp27,28. Although dHSC
activity has previously been observed from cultured pre-
circulation embryos, this activity was low, and only observed
after transplantation into Rag2γc−/− immunocompromised
recipients12. Here, we sought to determine if it might be possible
to coax robust dHSC activity from E8-E8.5 concepti.
We collected CD45.2+ embryos at E8.0-E8.5 and staged them
by number of somite pairs. Concepti were organized into two
groups: 2–3sp (pre-circulation) and 5–7sp (peri-circulation).
Embryos were separated from the YS and cultured at the air-
liquid interface in the presence of SCF, FLT3L, and IL-3, as
previously described29–31. We hypothesized that an extended
culture period might be required for maturation of dHSC from
these early embryos (Fig. 1a). Hence, embryos were cultured for
9–10 days. Cultured Em-Ex were then recovered, dissociated and
transplanted into lethally irradiated CD45.1+CD45.2+ recipients
along with 2 × 105 CD45.1+ whole bone marrow (WBM) cells for
radio-protection (Fig. 1a). Remarkably, both 2–3sp and 5–7sp
cultured embryos generated robust dHSC activity. 5–7sp embryos
engrafted 9/11 (82%) recipients while 2–3sp embryos engrafted
5/7 (71%) recipients (Fig. 1b). Globally, >15% of recipient
peripheral blood (PB) was CD45.2+ in 7/18 total recipients
at 16 weeks post-transplant. Four recipients displayed >50%
CD45.2+ PB reconstitution (Fig. 1b). Importantly, most engrafted
recipients (11/14) displayed multi-lineage engraftment at 16 weeks
post-transplant (Fig. 1b). To further test if Em-Ex developed
robust dHSC activity, we performed secondary limiting dilution
transplants. 0.8 × 106 (n= 9), 1 × 106 (n= 6), 2 × 106 (n= 8) or
5 × 106 (n= 8) WBM cells from three independent primary
recipients of 5–7sp Em-Ex were transplanted into lethally
irradiated CD45.2+CD45.1+ recipients (Fig. 2a). At the three
highest doses of WBM, 100% of secondary recipients displayed
significant Em-Ex-derived CD45.2+ chimerism (1–92%) at
16 weeks post-transplant (Fig. 2a). CD45.2+ reconstitution was
>25% in 11/31 secondary recipients and >90% in two recipients.
Multiple independent secondary recipients also yielded robust
long-term Em-Ex-derived CD45.2+ chimerism after transplanta-
tion into lethally irradiated CD45.1+CD45.2+ tertiary recipients,
although interestingly this reconstitution displayed dramatic
lineage skewing (Fig. 2b). The robust hematopoietic reconstitu-
tion of primary, secondary, and tertiary recipients by cultured
5–7sp Em-Ex is indicative of self-renewing dHSC and long-term
repopulating cells, confirming that our explant culture system
supports the emergence and maturation of dHSC from embryos
isolated at the onset of blood circulation.
Pre and peri-circulation YS do not produce dHSC ex vivo.
Dissected CD45.2+ YS from pre-circulation and peri-circulation
concepti (2–3sp and 5–7sp) were cultured as explants (YS-Ex) in
parallel and under the same conditions as Em-Ex. None of the
cultured pre-circulation or peri-circulation CD45.2+ YS-Ex yiel-
ded detectable dHSC activity when transplanted into lethally
irradiated CD45.1+CD45.2+ recipients along with 2 × 105 WBM
CD45.1+ cells (0/5 and 0/11 recipients, respectively, Fig. 1b). It is
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possible that YS hemogenic precursors undergo distinct temporal
maturation compared to intra-embryonic hemogenic endothe-
lium. Indeed, YS-Ex displayed substantially greater CFU-GEMM
(i.e., colony forming unit granulocyte, erythrocyte, monocyte,
megakaryocytic) potential at day 5 versus day 10 of ex vivo cul-
ture (Supplementary Fig. 1A). Thus, 5–7sp YS-Ex were cultured
for five or seven days prior to dissociation and transplanted into
lethally irradiated recipients. These cultures also failed to produce
detectable dHSC activity (0/8 for five-day YS-Ex cultures and 0/3
recipients for seven-day YS-Ex, Fig. 1c).
These data indicate that the only precursors capable of
maturing into functional dHSC under these conditions are found
in the embryo at this early stage of development. Additionally, we
tested the ability of YS isolated from later developmental time-
points (e.g., E9.5 (19–22 sp, n= 3), E10.5 (32–36 sp, n= 3) and
E11.5 (46–47sp, n= 7)) to engraft lethally irradiated recipients
after being cultured ex vivo for five days prior to transplantation.
100 and 71% of CD45.1+CD45.2+ recipients transplanted
with CD45.2+ E10.5 and E11.5 cultured YS-explants showed
robust CD45.2+ YS-derived engraftment, respectively (Fig. 1c).
In contrast, CD45.1+CD45.2+ recipients transplanted with
CD45.2+ E9.5 YS-derived explants displayed no evidence of
CD45.2+ engraftment (Fig. 1c). To test if E9.5 hematopoietic
precursors are capable of maturing into dHSC under our ex vivo
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Fig. 2 Pre-circulation Em-Ex display serially transplantable multi-lineage potential. a Left panel: Total WBM was isolated from three primary recipients of
CD45.2+ 5–7sp Em-Ex-derived cells and transplanted separately into three secondary cohorts of lethally irradiated CD45.1+CD45.2+ recipients. Mice
received 0.8 × 106 (n= 9), 1 × 106 (n= 7), 2 × 106 (n= 8) or 5 × 106 (n= 8) total WBM cells. Data pooled from three independent experiments is shown.
Non-engrafted mice are depicted as triangles. Means are shown. Error bars denote standard deviation. Right panel: Frequency of myeloid cells, T cells and B
cells in CD45.2+ PB of secondary recipients of 5–7sp Em-Ex 16 weeks post-transplant. b 5 × 106 WBM cells from secondary recipients of 5–7sp Em-Ex were
transplanted into CD45.1+CD45.2+ mice along with 2 × 105 CD45.1+ WBM cells. Bone marrow from n= 4 independent secondary recipients were
transplanted into independent cohorts of tertiary recipients. Secondary donors A, B, and C derived from the same initial primary recipient. Secondary donor
D derived from an independent primary recipient. Left panel: %CD45.2+ tertiary recipient PB cells. Four (white circles) and 16 (black circles) weeks post-
transplant. Donors A, B, and C (n= 5 recipients); Donor D (n= 10 recipients). Each circle indicates an independent tertiary recipient. Means and standard
deviations are depicted. Right panel: Frequency of myeloid cells, T cells and B cells in CD45.2+ PB of tertiary recipients 16 weeks post-transplant. Each
column corresponds to an independent recipient. Source data are provided as a Source Data file
Fig. 1 Pre-circulation embryos but not YS yield robust dHSC activity. a Experimental schematic. Em and YS were dissected from E8-E8.5 (2–7sp) concepti
and cultured as explants at the air-liquid interface for 9–10 days. Explants were then harvested, dissociated and transplanted at ≥four embryo equivalent (e.
e.)/recipient. b Left panel: CD45.2+ (i.e., 2–3sp Em-Ex (n= 7), 5–7sp Em-Ex (n= 11), 2–3sp YS-Ex (n= 5) or 5–7sp YS-Ex (n= 11)) contribution to PB of
primary recipients. Data pooled from 16 independent experiments. Generally, tissues from one independent litter were transplanted per experiment. For
2–3sp explants, all YS-Ex (n= 5) were transplanted in parallel with Em-Ex isolated from the same concepti. For 5–7sp explants, all YS-Ex (n= 11) were
transplanted in parallel with at least one Em-Ex isolated from the same concepti as a positive control for engraftment (**p < 0.01, eWrs-test). Right panel:
Frequency of myeloid cells, T cells and B cells in CD45.2+ PB and representative flow cytometry plots of primary recipients of 2–3sp and 5–7sp Em-Ex
16 weeks post-transplant. Each column represents an independent recipient. For the 5–7sp Em-Ex, only the engrafted mice are shown (n= 9). c CD45.2+
YS were isolated from E8.5 (5–7sp, n= 8 recipients), E9.5 (19–22sp, n= 3 recipients), E10.5 (32–36sp, n= 3 recipients) or E11.5 (46–47sp, n= 7
recipients) concepti, cultured as explants for five or seven days and then transplanted at eight ee/recipient. Data pooled from five independent
experiments. (*p < 0.05, eWrs-test). d YS-Ex and Em-Ex were isolated from CD45.2+ E9.5 (19–22sp) concepti and cultured under the same conditions as
in b for five (n= 3 recipients), seven (n= 6 recipients) or 10 days (n= 3 recipients) before transplantation into lethally irradiated recipients at eight ee/
recipient. Statistical differences between Em-Ex and YS-Ex are indicated (**p < 0.01, *p < 0.05, #p < 0.1, two-sample t-test and eWrs-test). b–d %CD45.2+
PB (i.e., YS-Ex or Em-Ex-derived) was examined in recipients four and 16 weeks post-transplantation. Each circle represents an independent recipient. For
all panels, gray or pink and black or red circles indicate four and 16 weeks post-transplant, respectively. Means and standard deviations are shown. Source
data are provided as a Source Data file
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culture conditions, embryonic caudal halves and YS isolated from
CD45.2+ E9.5 concepti were cultured for five, seven or 10 days
and then transplanted into lethally irradiated CD45.1+CD45.2+
recipients (Fig. 1d). 100% of recipients transplanted with
embryonic caudal halves cultured for five or seven days (3/3
and 6/6, respectively, Fig. 1d) displayed robust CD45.2+ dHSC
activity, confirming that post-circulation E9.5 dHSC can mature
under these culture conditions. However, all E9.5 YS-derived
explants failed to generate detectable dHSC in these experiments
(Fig. 1d).
In sum, these findings support a model where the precursors in
pre-circulation and peri-circulation concepti capable of maturing
into functional dHSC under these conditions are located in the
embryo.
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SCF and IL-3 induce CD31+CD45+c-Kit+CD41− dHSC
emergence. We next sought to phenotypically characterize func-
tional dHSC that emerge during the ex vivo culture of peri-
circulation Em-Ex. We took advantage of cell surface markers to
isolate distinct populations from CD45.2+ 5–7sp Em-Ex for
transplantation into lethally irradiated CD45.1+CD45.2+ recipients
(Fig. 3a). Previous work showed that dHSC activity in E10.5-E11
Em-Ex cultured under similar conditions is contained in the
CD31+CD45+ fraction29,31. This population was apparent in the
Em-Ex cultures (Fig. 3b). CD41 and c-Kit are also expressed by
nascent hematopoietic populations in early embryos30–38. Distinct
populations expressing both CD41 and c-Kit were clear within
CD31+CD45+ Em-Ex cells (Fig. 3b, Fig. 4b and Supplementary
Fig. 1B). We therefore isolated CD31+CD45+c-Kit+CD41+,
CD31+CD45+c-Kit+CD41−and CD31+CD45+c-Kit− cells by
FACS from cultured 5–7sp Em-Ex and transplanted them into
lethally irradiated CD45.1+CD45.2+ recipients (n= 5, Fig. 3a–c).
All dHSC activity was restricted to CD31+CD45+c-Kit+CD41-cells
(Fig. 3c). Interestingly, this same population was also apparent in
5–7sp YS cultures (Fig. 4b and Supplementary Fig. 1B).
We next tested whether the emergence of the CD31+CD45+c-Kit
+CD41− engrafting population was selectively dependent on any of
the three growth factors added to these cultures (i.e., SCF, IL-3,
FLT3L). Embryos and YS isolated from 5–7sp concepti were
cultured in the presence of different combinations of growth factors
and assessed by flow cytometry for the emergence of
CD31+CD45+ and CD31+CD45+c-Kit+CD41− cells (Fig. 3d, e).
CD45.2+ Em-Ex cultures were also transplanted into lethally
irradiated CD45.1+CD45.2+ recipients to test for dHSC activity
(Fig. 3d, f). Removal of FLT3L had no effect on the frequency of
CD31+CD45+ or CD31+CD45+c-Kit+CD41− cells in YS-Ex or
Em-Ex cultures (Fig. 3e). Moreover, removal of FLT3L did not affect
the emergence of dHSC in Em-Ex cultures: the contribution of
CD45.2+ cells to the PB of transplant recipients was 18% in the
presence of all three factors and 21% in the absence of FLT3L
(Fig. 3e, f and Supplementary Fig. 1B). In contrast, removal of IL-3
or SCF reduced the frequency of CD31+CD45+ or CD31+CD45+c-
Kit+CD41− cells, respectively, in YS-Ex and Em-Ex cultures, which
correlated with a loss of dHSC activity from CD45.2+ Em-Ex
cultures (Fig. 3e, f and Supplementary Fig. 1B). The average
CD45.2+ hematopoietic reconstitution in these recipients dropped
to about 5 and 10% in the absence of IL-3 or SCF, respectively
(Fig. 3f). Em-Ex cultured in the absence of both FLT3L and IL-3
also displayed reduced hematopoietic engraftment potential (p < 0.1,
exact Wilcoxon rank sum test (eWrs-test)) (Fig. 3f). Em-Ex
cultured in the absence of all three cytokines displayed dramatic
reductions in the frequency of CD31+CD45+ and CD31+CD45+c-
Kit+CD41− cells and lacked detectable dHSC activity (Fig. 3e, f and
Supplementary Fig. 1B). In sum, administration of both SCF and IL-
3 is required for the efficient development of CD31+CD45+
c-Kit+CD41− cells from pre-circulation concepti during YS-Ex
and Em-Ex culture and dHSC potential in Em-Ex cultures. These
results are consistent with the observation that SCF and IL-3 can
both promote the in vitro derivation of bona fide HSC from other
cell sources29–31,39–41.
An HSC-like population is generated by embryo explants. YS
and embryos are separated and cultured before the onset of the
circulation in our experimental platform. Thus, this represents an
opportunity to selectively study embryo versus YS-derived
hematopoiesis under controlled conditions that allow for the
maturation of dHSC from early embryonic precursors. Indeed,
novel cell surface markers of dHSC-derived from early embryos
could be useful reporters in efforts to isolate dHSC from plur-
ipotent stem cells or other sources. Although CD31+CD45+c-Kit
+CD41−cells develop in both YS-Ex and Em-Ex cultures, cul-
tured YS-Ex-CD31+CD45+c-Kit+CD41− cells do not harbor
dHSC activity (Figs. 1b, 3b, 3f, Supplementary Fig. 1B). Therefore,
we decided to interrogate the gene expression profiles of 5–7sp
YS-Ex-CD31+CD45+c-Kit+CD41− cells and Em-Ex-CD31
+CD45+c-Kit+CD41− cells on day 10 post-culture for molecu-
larly distinct cell populations that might explain the absence of
dHSC activity in YS explants by single cell RNA sequencing
(scRNAseq) (Fig. 4).
First, we determined the frequency of the engrafting population
within cultured Em-Ex. Limiting dilution transplantation
revealed 0.83 repopulating units (RUs) per Em-Ex (95% C.I.=
(0.48, 1.42); results fit the LDA model: p-value= 0.717, t-test)
(Fig. 4a). Next, 49 concepti were dissected and cultured as
separate YS-Ex and Em-Ex for scRNAseq. In this experiment we
are interrogating approximately 40.67 RUs in the Em-Ex sample
(i.e.,: 49Em-Ex*0.83RUs).
To identify Em-Ex-derived populations of putative biological
interest, the resulting scRNAseq data was projected as tSNE1 Vs
tSNE2. A population specific to the Em-Ex sample was apparent
(X-cells, Fig. 4c). It was comprised of 623 cells (17.8% of the Em-
Ex population). To interrogate the developmental state of this
population, we compared its expression profile to Zhou and
colleagues scRNAseq dataset of embryonic hematopoiesis
(Fig. 4d)42. Em-Ex cells were most similar transcriptionally to
E11-T2-pre-HSC (CD31+CD45+cKit+CD41low, 60% of the X-
Fig. 3 HSC potential is restricted to CD31+CD45+c-Kit+CD41− embryo explant cells and requires SCF and IL-3. a Experimental schematic. Embryos
isolated from E8.5 (5–7sp) concepti were cultured as in Fig. 1b, dissociated and fractionated by FACS based on CD31, CD45, and c-Kit cell surface
expression and then transplanted at four ee/recipient into lethally irradiated CD45.1+ CD45.2+ recipients along with 2 × 105 CD45.1+ WBM cells.
b Representative flow cytometry plots denoting sorted and transplanted populations (A: CD31+CD45+c-Kit+CD41+; B: CD31+CD45+ c-Kit+CD41−; C:
CD31+CD45+c-Kit−). c %CD45.2+ PB of recipients at four (light-colored circles) and 16 weeks (dark-colored circles) post-transplant. Each circle
represents an individual recipient. Five independent experiments are depicted. In each experiment all sorted cells for each population were transplanted
into one separate recipient. Engraftment was only detected upon transplantation of population B. d Experimental schematic. E8.5 (5–7sp) YS-Ex and Em-Ex
were cultured at the air-liquid interface for 9–10 days in different combinations of SCF, FLT3L and IL-3 and either analyzed by flow cytometry or
transplanted to test for dHSC. e Cultured explants were analyzed by flow cytometry for CD31+CD45+ and CD31+CD45+c-Kit+CD41−cells after 5 (n= 2,
with the exception of Em-Ex SCF+ IL-3+ FLT3L+ , Em-Ex SCF+ IL-3+ and Em-Ex IL-3+ FLT3L+where n= 3) or 10 days of culture (n= 3, with the
exception of Em-Ex SCF+ IL-3+ FLT3L+ , Em-Ex SCF+ IL-3+ and Em-Ex IL-3+ FLT3L+where n= 4). Each circle represents an individual culture. Bars
stand for average. Results from four independent experiments are shown. Left panel: Em-Ex-explants. Right panel: YS-Ex. Statistical differences with the
SCF+ Flt3l+ IL-3+ control are indicated: (*p < 0.05 and **p < 0.01, two-sample t-test). f CD45.2+ Em-Ex were transplanted into lethally irradiated CD45.1
+CD45.2+ recipients at four ee/recipient along with 2 × 105 CD45.1+ WBM cells. %CD45.2+ PB four (gray circles) and 16 weeks (black circles) post-
transplant is shown. Each circle represents an individual recipient. Cumulative data from 13 independent experiments. The majority of the analyzed
conditions yielded an engraftment that was marginally statistically higher than the No-Growth Factor condition (**p < 0.01, *p < 0.05, #p < 0.1; eWrs-test
and two-sample t-test). Horizontal bars indicate averages. Error bars denote standard deviation. Source data are provided as a Source Data file
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cells were assigned to this group) or E12.5 Fetal Liver (FL) HSC
(Lineage−Sca-1+Mac-1lowCD201+, 37% of the X-cells were
assigned to this group) and thus ‘assigned’ to these populations
computationally (Fig. 4d). Interestingly, Em-Ex-derived X-cells
were highly enriched for cells assigned to FL HSC. Indeed, 70 and
6% of Em-Ex-derived X-cells were assigned to E12.5 FL HSC and
E14.5 FL HSC (CD45+CD150+CD48−CD201+), respectively
(Fig. 4d). These data suggest that X-cells are enriched for
developmentally more mature hematopoietic progenitors43.
Interestingly, the vast majority of profiled YS-Ex cells (92%)
were assigned to E11.0-T2-pre-HSC, suggesting developmental
immaturity relative to Em-Ex cells (Fig. 4d). A comparison of
E11.0-T2-pre-HSC and E12.5-FL HSC revealed 353 down-
regulated genes and 80 upregulated genes (FDR<0.05 and Log2
fold change <−2 or >2, respectively; eWrs-test and Benjamini and
Hochberg p-value adjustment) (Fig. 4e). Remarkably, compared
to other analyzed cells in our scRNAseq dataset, X-cells showed
lower expression for the downregulated genes and higher
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expression for the upregulated genes (Fig. 4f). Upregulated genes
were enriched in proliferation related functional terms (i.e., E2F
cell cycle targets and DNA-repair genes (FDR q-values= 3.98 ×
10−3 and 1.58 × 10−2, respectively; Fisher’s exact test and
Benjamini and Hochberg p-value adjustment). This is consistent
with increasing proliferation as HSC transition from the AGM
to the FL1. Genes defining epithelial-to-mesenchymal down-
regulated in the E11.0-pre-HSC to E12.5-HSC transition were
also downregulated in the X-cells (FDR q-value= 2.85 × 10−6;
Fisher’s exact test and Benjamini and Hochberg p-value
adjustment). Of note, multiple cell surface proteins appear
selectively upregulated in Em-Ex X-cells (e.g., Cxcr4, Mpl, Il6ra,
and Tnfrsf1, Supplementary Fig. 2). Further work will be required
to determine if these cell surface markers hold functional utility
for further enrichment of transplantable dHSC from Em-Ex.
Indeed, identifying a specific marker for embryonic populations
with bona fide dHSC potential could be very useful for in vitro
screens.
Intraembryonic LYVE1+ blood precursors yield dHSC activity.
Our studies suggest that the pre-circulation and peri-circulation
YS is not a major source of dHSC. However, it was recently
reported that >40% of adult blood may emerge from the early YS
and vitelline endothelium14. Lee and colleagues used Lyve1-eGFP-
hCre knock-in mice (Lyve1Cre) (Fig. 5a) to claim an extra-
embryonic origin for a significant fraction of adult blood, but not
primitive erythrocytes or the definitive hematopoietic precursors
of the embryo, placenta or umbilical vessels. LYVE1 expression
was reportedly highest in the endothelium of the YS and vitelline
vessels (VV) in the mid-gestation conceptus14.
We used Lyve1Cre, Rosa26+/mTmG and Rosa26+/Confetti mice to
further examine the contribution of LYVE1+ cells to lifelong
hematopoiesis. The unrecombined Rosa26mTmG allele ubiqui-
tously labels all cells with the tdTOMATO protein (Fig. 5a). CRE
recombinase (CRE) drives the excision of the tdTomato cassette
and stably labels CRE+ cells and their progeny with GFP (Fig. 5a)
44. The unrecombined Rosa26Confetti multicolored cassette does
not drive any fluorescent expression. Here, CRE induces
recombination of the Rosa26Confetti allele, which results in cells
and their progeny stably labeled with one of four fluorescent
proteins (GFP, CFP, RFP, or YFP, Fig. 5a)45. We observed ≈20
and ≈5% labeled cells in the adult blood of Lyve1+/CreRosa26
+/mTmG and Lyve1+/CreRosa26+/Confetti mice, respectively
(Fig. 5b), confirming that cells expressing CRE via the Lyve1Cre
allele at some point during their development contribute to adult
hematopoiesis, albeit in our hands less than the 40% previously
reported14. Similar to previous reports, we observed that the
endogenous eGFP signal from the Lyve1Cre knock-in allele
(Fig. 5a) was faint and did not hinder detection of the eGFP
signal from the Rosa26mTmG reporter allele14,46.
To further interrogate LYVE1 as a marker of early hemato-
poietic progenitors, we next assessed LYVE1 expression in post-
circulation concepti. We observed both LYVE1low and LYVE1high
cells in E9.5 (19–22sp) and E10.5 (32–36sp) YS and embryos
(Fig. 5c–f). Most embryo LYVE1+ cells were LYVE1low
(Fig. 5c–f). Indeed, at E9.5 and E10.5 the absolute numbers of
embryo- and YS-LYVE1lowVE-Cadherin+CD31+CD41+c-Kit+
cells were not significantly different (Fig. 5d, f). Thus, LYVE1
expressing cells are readily detectable in post-circulation embryos
and YS. Further, examination of public gene expression databases
revealed Lyve1 mRNA in dHSC precursors in E11-E11.5AGM
(Supplementary Fig. 3)42,43. Altogether, these data confirm that
LYVE1 is expressed by putative hematopoietic progenitors in
both YS and embryonic tissues post-circulation14.
Next, we examined LYVE1 expression in peri-circulation
(5–7sp concepti) mouse concepti using flow cytometry and
confocal microscopy. We again observed distinct LYVE1high and
LYVE1low populations in both YS and embryos (Fig. 6a).
Although both populations were more abundant in YS relative
to embryos, especially LYVE1high cells, LYVE1 expressing cells
were clearly detectable by flow cytometry in 5–7sp embryos (% of
YS-LYVE1high = 2.86; % of Em-LYVE1high = 0.11; % of YS-
LYVE1low = 3.11; % of Em-LYVE1low = 0.56) (Fig. 6a, b). Most
LYVE1high and LYVE1low cells in both 5–7sp YS and embryos
also expressed CD41 (≈70 and ≈85%, respectively, Fig. 6a, c).
Moreover, LYVE1+CD31+ cells were apparent in the endothe-
lium of the paired aorta of E8.5 embryos (Fig. 6d). Altogether,
these data demonstrate that LYVE1 expression is not restricted to
YS in peri-circulation embryos.
To gain further insight into the fidelity of LYVE1 as a specific
marker of YS and vitelline hemogenic endothelium, YS and
embryos were collected at the onset of the heartbeat from 5–7sp-
Lyve1+/CreRosa26+/mTmG concepti (Fig. 7a). Here, GFP+ cells
were readily detected in YS (Fig. 7b, c), with an average frequency
of 3.9% (Fig. 7c). Labeled cells were much less frequent in 5–7sp
embryos (average labeling of 0.067%, Fig. 7b, c). We previously
observed that the vast majority of LYVE1+ cells in Lyve1
+/+Rosa26+/+ concepti are CD41+ (Fig. 6c). Similarly, most GFP
+ cells in 5–7sp Lyve1+/CreRosa26+/mTmG concepti were CD41+
(Fig. 7b, d). Additionally, the %CD41+ cells was about 20 times
larger in the YS than in the embryo (Fig. 7e). As CD41 labels
hematopoietic precursors at this early developmental stage, we
focused on the recombination efficiency in the CD41+
Fig. 4 scRNAseq analysis identifies a rare HSC-like population specific to embryo explant cultures. a Limiting dilution transplantation of Em-Ex cells. One,
two or three embryo equivalents were transplanted/recipient. Data pooled from three independent experiments. Left panel: Experimental schematic.
Middle panel: %CD45.2+ PB of recipients at 16 weeks post-transplant. Each circle represents an individual recipient. Red circles highlight non-engrafted
recipients. The number of mice engrafted/number of recipients at each cell dose is shown. Right panel: χ2 analysis revealed a fit to the limiting dilution
model (p-value= 0.717; t-test). The Log of the non-responding fraction is shown for each cell dose. b Representative FACS plots showing sorting strategy
for CD31+CD45+c-Kit+CD41− cells in YS-Ex and Em-Ex after 10 days of culture. 49 E8.5 concepti (5–7sp) were dissected, cultured and cells of interest
collected by FACS. Post-sort purity check of sorted populations are shown. c Single cell global gene expression analysis of Em-Ex- and YS-Ex-CD31+CD45
+c-Kit+CD41− cells. Projection of single cell gene expression profiles onto tSNE1 (X-axis) versus tSNE2 (Y-axis) with Em-Ex cells in pink and YS-Ex cells in
blue. X denotes the Em-Ex sub-population circled in red. (n= 3504 Em-Ex cells; n= 3037 YS-Ex cells) d Maturation stage analysis. Identified population
was compared to available profile expression datasets on embryonic pre-HSC and HSC from Zhou et al.42. Assignment of cultured YS-Ex, Em-Ex and X-
cells to embryonic hematopoietic populations. From the AGM: E11_EC (E11-Endothelial cells; CD31+VE-cadherin+CD41−CD43−CD45−Ter119−); E11_T1
(E11-pre-HSCs; CD31+CD45−CD41lowc-Kit+ CD201high); E11_T2_CD201neg (E11-pre-HSCs; CD31+CD45−CD41lowc-Kit+CD201−); E11_ T2 (E11-AGM
−CD31+CD45+CD41low CD201high); from the fetal liver, E12.5_FL (HSCs, Lin−Sca-1+Mac-1lowCD201+; E14.5_FL (HSC, CD45+CD150+CD48−CD201+);
and Adult HSC (BM-HSC, CD45+CD150+CD48−CD201+). e Volcano plot of differentially expressed genes between E11_T2 and E12.5_FL. Downregulated
genes are shown in blue and upregulated in red, (FDR<0.05 and Log2 fold change <−2 or >2, respectively. f Pattern of the 80 most differentially expressed
genes in X-population. Source data are provided as a Source Data file
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compartment and found it to be about 5% in the YS and 1.1% in
the embryo (Fig. 7f)30,32–34,36,37. Importantly, GFP+ cells in E8.5
embryos were confined to the endothelium of the paired aortas
(Fig. 7g).
As our explant culture system allows us to visualize the
emergence of phenotypic hematopoietic precursors from pre-
circulation and peri-circulation concepti, we next examined GFP
labeling in cultured YS-Ex and Em-Ex-derived hematopoietic
precursors (CD31+CD45+c-Kit+CD41−). We observed that, on
average, 61% of YS-Ex-derived and 47% of Em-Ex-derived CD31
+CD45+c-Kit+CD41−cells were GFP+ (Fig. 7h, i). Lethally
irradiated CD45.1+CD45.2+ recipients were next transplanted
with cells isolated from Lyve1+/CreRosa26mTmG 5–7sp Em-Ex
and 2 × 105 CD45.1+ WBM cells (Fig. 7j-l). As expected from our
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previous experiments (Fig. 1b), 5–7sp Lyve1+/CreRosa26mTmG
cultured Em-Ex harbored dHSC activity and reconstituted
15–80% of recipient PB (Fig. 7k). Importantly, 3/4 recipients of
E8.5 Lyve1+/CreRosa26mTmG-derived Em-Ex displayed GFP+
engraftment, demonstrating that Lyve1Cre labels the progeny of
intra-embryonic HE precursors (Fig. 7l). Indeed, in one recipient,
88% of Em-Ex-derived PB was GFP+ (Fig. 7l). Differences in the
%GFP+ recipient PB reflects the small number of Em-Ex-derived
RUs transplanted per recipient (3.32 RUs= 4EE*0.83RUs per
explant, Fig. 4a) and low recombination efficiency of the
Rosa26mTmG allele (about 20%, Fig. 5b). We also tested cells
isolated from 19–22sp Lyve1+/CreRosa26mTmG Em-Ex and YS-Ex
for dHSC activity via transplantation. Here, Em-Ex-derived PB
reconstitution was high (averaging 51%, n= 10). Although the %
GFP+ PB varied widely (Fig. 7l), 8/10 recipients displayed GFP+
PB reconstitution. As expected (Fig. 1c, d), Lyve1+/CreRo-
sa26mTmG YS-Ex did not engraft recipient mice (Fig. 7k, l). In
sum, our data reveal that the embryo harbors LYVE1+ blood
precursors capable of giving rise to dHSC.
Discussion
Identifying the original site of dHSC specification during
embryogenesis has been a major challenge due to the migratory
nature of blood precursors in the circulating embryo and the
absence of assays to rigorously test hematopoietic potential of
pre-circulatory tissues. Here, we report the robust generation of
dHSC activity from pre-circulation and peri-circulation murine
embryos. dHSC activity could only be detected in cultured
embryo explants and not cultured YS explants, indicating that the
YS is unable to autonomously generate dHSC activity, at least
under the conditions tested here. This implies that either the YS
does not contain dHSC precursors or that it lacks the essential
support environment for maturation of such precursors. Our
findings are consistent with those of Cumano and colleagues, but
in those studies, the authors were only able to detect very low
levels of HSC activity from pre-circulation intra-embryonic tis-
sues (<5%), and only after transplantation into immunocom-
promised Rag2γc−/− recipients12. Poor reconstitution activity left
open the possibility that YS harbored dHSC activity that fell
below their detection threshold. Indeed, very recent studies sug-
gest an extraembryonic (i.e., YS and/or vitelline hemogenic
endothelium) origin for a large fraction of lifelong
hematopoiesis13,14. However, the high levels of dHSC activity
detected in our culture system (up to >75% reconstitution of PB
after transplantation into immunologically competent mice)
allows us to rigorously compare YS and embryos and demon-
strate that pre-circulation YS lacks significant dHSC potential
(Fig. 1b). None-the-less, our data support a model in which dHSC
originate from intra-embryonic precursors in pre-circulation and
peri-circulation concepti.
CD31+CD45+c-Kit+CD41−cells harbored all Em-Ex-derived
dHSC activity in our experimental system. The development of
this population required exogenous administration of SCF and
IL-3 (Fig. 3). This agrees with previous studies where SCF is also
required for the maturation of E9.5 pro-HSCs and E10.5 type I
and type II pre-HSCs. Scf is expressed in the E9.5 dorsal aorta and
upregulated at E10.5 when HSPC specification accelerates29–31.
Scf−/− mice display reduced dHSC activity and peri-natal
death39. IL-3 induces maturation of dHSC between E10.5 and
E11.5 in the AGM40,41. In contrast, exogenous administration of
FLT3L is dispensable for dHSC maturation ex vivo31. Our finding
that 5–7sp Em-Ex also require SCF and IL-3 to effect dHSC
maturation ex vivo suggests that even very early dHSC precursors
require these same signals.
Interestingly, CD31+CD45+c-Kit+CD41− cells also emerged
in cultures of early YS (Fig. 4b), where they clearly lack detectable
dHSC activity (Fig. 1b–d). The ability of our culture conditions to
yield bona fide dHSC from pre-circulation concepti provides a
unique opportunity to study YS-specific and embryo-specific
hematopoiesis and the critical molecular features that allow Em-
Ex to render dHSC activity. This could be useful for efforts to
derive bona fide dHSC from alternative sources ex vivo and
provide specific reporters for in vitro screening. Remarkably,
single cell global gene expression profiling identified an Em-Ex-
derived population (X-cells, Fig. 4c) that does not emerge from
YS cultures and displays enrichment for genes expressed by dHSC
found in the FL (Fig. 4d). Further analysis identified multiple cell
surface molecules selectively expressed by this unique population
(e.g., Cxcr4, c-Mpl, Il6ra, and Tnfrsf1, Supplementary Fig. 2).
These cell surface markers harbor putative utility to both refine
the Em-Ex population harboring dHSC activity and explore for
in vivo surrogates that may represent critical transitions in the
maturation of dHSC in vivo. Exploring the biological significance
of these and other markers will be the subject of future
investigations.
An alternative approach to defining the embryonic origins of
lifelong hematopoiesis is the use of YS versus embryo-specific
lineage markers. This approach has proved challenging as YS and
embryo-derived hematopoietic precursors exhibit similar devel-
opmental programs1. Both are mesodermal in origin and emerge
from endothelial precursors. Previously, temporally controlled
Runx1−based lineage tracing suggested YS-derived contribution
to adult hematopoiesis13. However, the duration of the labeling
pulse was unclear and only a low percentage of adult blood cells
were labeled1,13. Additionally, RUNX1+ cells were apparent
Fig. 5 LYVE1 is expressed by E9.5-E10.5 putative hematopoietic progenitors in embryonic and YS tissues. a Left panel: Schematic of Lyve1−eGFP-hCre
knock-in allele (Lyve1Cre). Adapted from ref. 41. Middle panel: Schematic of the Rosa26mTmG allele39. The membrane-targeted tandem dimer tomato (mT)
protein is expressed from the unrecombined allele under the chicken β-actin core promoter with a CMV enhancer (pCA). Cre expression excises the mT
cassette and results in expression of the membrane-targeted enhanced green fluorescent protein (mG). mT protein pA indicates polyadenylation
sequences and black triangles are loxP sites. Right panel: Schematic of ROSA26Confetti allele. Unrecombined allele does not yield the expression of any
fluorescent protein. Cre recombinase expression results in a two-steps recombination event that renders the expression of one of the four Confetti-colors
(GFP, YFP, RFP, or CFP)40. b Left panel: %recombination (i.e., GFP+) in Lyve1+/CreRosa26+/mTmG PB at 2 months of age (n= 8). Right panel: %
recombination (i.e., %Confetti+ ) inLyve1+/CreRosa26+/Confetti PB (n= 8). Labeling efficiencies of total white blood cells, B-cells, T-cells and myeloid cells
are shown. Average is depicted (error bars indicate ± s.d. of mean). c–d Cell surface expression of LYVE1 in YS and embryos dissected from freshly isolated
E9.5 (19–22sp) concepti (n= 14). c Representative flow cytometry plots. d The absolute number/concepti and frequency as a percent of total live events of
LYVE1low and LYVE1high cells within the VE-Caderin+CD31+CD41+c-Kit+ compartment is shown. Two independent litters were analyzed. e–f LYVE1
expression in freshly isolated E10.5 (32–36sp) concepti (n= 20). The absolute number/concepti and frequency as a percent of total live events of LYVE1low
and LYVE1high cells within VE-Caderin+CD31+CD41lowc-Kit+ cells is shown. Three independent litters were analyzed. Each circle represents an
independent YS or embryo. Means and standard deviations are shown. (***p < 0.001, two sample t-test and eWrs-test; differences held even after multiple
testing corrections to control a FDR of 0.05). Source data are provided as a Source Data file
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07769-8
10 NATURE COMMUNICATIONS |          (2018) 9:5405 | https://doi.org/10.1038/s41467-018-07769-8 | www.nature.com/naturecommunications
E8.5 (5–7sp)
YS
E8.5 (5–7sp)
FSC
4.9%
4.27%
89.5%
Emb
FSC
0.14%
0.94%
98.6%
22.3%
73.5%
32.1%
20.4%
38%
35.1%
28.6%
60.7%
8.7%
63.6%
0.16%
1.4%
CD41-PerCPe710
LY
V
E
1-
P
E
CD41-PerCPe710 
LY
V
E
1-
P
E
LY
V
E
1-
P
E
LY
V
E
1-
P
E
a
0
50
100
%
C
D
41
+
LYVE1low LYVE1high
Emb YS
***
E8.5 (5–7sp)
0
1
2
3
4
5
0
100
200
300
400
500
600
700
N
o.
 o
f  
LY
V
E
1l
ow
%
  o
f  
LY
V
E
1l
ow
Emb YS Emb YS
*** ***
0
2
4
6
8
N
o.
 o
f L
Y
V
E
1h
ig
h
%
  o
f L
Y
V
E
1h
ig
h
Emb YS Emb YS
***
***
0
200
400
600
800
1000
A
LYVE1MERGE CD31MERGEd
FG
NT
A
A
YS
A
NT
A
A
A
b
c
Fig. 6 LYVE1 is expressed by both yolk sac and embryo cells at E8.5. a Representative flow cytometry plots of LYVE1 expression in freshly isolated E8.5
(5–7sp) embryos and YS. b Cell surface expression of LYVE1 in YS and embryos dissected from freshly isolated E8.5 (5–7sp) concepti (n= 16). The
absolute number per concepti and frequency as a percent of total live events of LYVE1low and LYVEhigh cells is shown. Each circle represents an
independent YS or embryo. c Frequency of CD41+ cells as a percent of total live events of LYVE1low and LYVEhigh cells is shown (n= 16) for embryos
and YS. a–c Two independent litters were analyzed. (***p < 0.001, two-sample t-test for LYVE1low and eWrs-test LYVEhigh; differences held even after
multiple testing corrections to control a FDR of 0.05). Means are shown. Error bars denote standard deviation. d Representative confocal images showing
the pattern of expression of LYVE1 in E8.5 embryos and YS. Two independent embryos are shown. For each representative embryo an inset zoomed
on one of the paired aortas is also shown. Anti-LYVE1 conjugated to CFTM568 is shown in red and anti-CD31−BV421 is shown in blue. Scale bars stand
for 50 µm for the low magnification (i and iii) and 10 µm for the high magnification (ii and iv). Schematics indicate anatomical parts: FG: foregut; A: paired-
aorta; NT: Neural tube. Source data are provided as a Source Data file
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07769-8 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5405 | https://doi.org/10.1038/s41467-018-07769-8 | www.nature.com/naturecommunications 11
outside the YS, raising doubts that all Runx1-induced Cre
recombinase activity in early embryos was YS-restricted1,13.
Further, this study employed a Cre recombinase knock-in mouse
model that was hemizygous for Runx1. Runx1−/+ mice are
severely perturbed in both the timing of hematopoietic specifi-
cation and the cell surface phenotype of emerging hematopoietic
progenitors47. Thus, observations made in a hemizygous Runx1
mouse model are unlikely to reflect normal steady-state hema-
topoietic ontogeny.
It is possible that the YS harbors dHSC precursors that fail to
‘mature’ in our system due to the absence of key embryo-derived
non-cell-autonomous cues. In this scenario, YS-precursors may
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need to migrate to a maturation niche in the embryo, as proposed
by Matsuoka and colleagues18. Indeed, Runx1+Gata-1− (hemo-
genic angioblasts) have been reportedly observed migrating from
the E7.5 extraembryonic YS into the embryo proper in cultured
embryo explants, where they were proposed to receive a currently
undefined signal that induces competence to contribute to life-
long hematopoiesis19. However, here again the duration of the 4-
OHT labeling pulse was unclear, raising the possibility that rare
Runx1+ intraembryonic precursors could have been labeled
between E8 and E8.5. Further, it has not been explicitly demon-
strated that Runx1+Gata-1− cells seen migrating in ex vivo cul-
tures from the extra-embryonic to the intra-embryonic region are
capable of contributing to lifelong hematopoiesis in vivo. In our
explant system, pre-circulation and peri-circulation YS explants
failed to generate any dHSC activity.
Although, Lyve1−Cre lineage tracing was recently employed to
discern blood derived from YS versus embryonic endothelial
precursors14, we observed two distinct LYVE1+ populations
(LYVE1high and LYVE1low) in both YS and embryos isolated
from E8.5, E9.5 and E10.5 concepti (Figs. 5–6). Although the
frequency and absolute numbers of LYVE1high cells is higher in
the YS, the absolute numbers of LYVE1low cells between YS-
derived and embryo-derived blood precursors is not significantly
different (Figs. 5–6). Moreover, we observed LYVE1+ endothelial
cells in the endothelium of the paired embryo aortas prior to the
onset of circulation (Fig. 6d and Fig. 7g). Furthermore, Lyve1+/Cre
Rosa26+/mTmG embryos isolated at the onset of the first heartbeat
(5–7sp) and cultured as explants gave rise to GFP+CD31+CD45
+c-Kit+CD41− cells, which is the transplantable population that
emerges in this system (Fig. 3c and Fig. 7h, i). On average, about
50% of emerging CD31+CD45+c-Kit+CD41− cells were GFP+ in
these cultures, with one Em-Ex yielding 100% GFP+CD31+CD45
+c-Kit+CD41− cells (Fig. 3c and Fig. 7h, i). Most importantly,
transplantation of 5–7sp Lyve1+/Cre Rosa26+/mTmG Em-Ex
revealed that LYVE1+ embryo-derived progeny consistently
contributed to the engraftment of lethally irradiated recipients
(Fig. 7j–l). Thus, embryo-derived hematopoietic precursors must
also express LYVE1. Altogether, these data confirm LYVE1 as an
early marker of definitive hematopoiesis, reveal that LYVE1
expression is not restricted to YS hematopoietic precursors and
suggest that most LYVE1+ contribution to adult hematopoiesis is
embryonic in origin.
In summary, here we report the generation of robust dHSC
activity from pre-circulation and peri-circulation embryo
explants during ex vivo culture. Cultured YS explants failed to
yield dHSC activity under these same conditions, suggesting that
the YS contains few precursors capable of maturing into dHSC.
We also present evidence that both YS and embryo-derived
hemogenic precursors express LYVE1 during ontogeny. Our
study supports a model in which most of lifelong hematopoiesis
derives from hematopoietic precursors that develop de novo in
the embryo proper. Future studies will be required to better define
the pre-circulation and peri-circulation embryonic precursors
that ultimately mature into dHSC. These studies would benefit
any effort to coax bona fide dHSC from pluripotent stem cells.
Methods
Mice. C57BL/6 J, C57BL/6.SJL-PtprcaPep3b/BoyJ, ROSA26+/mTmG (Gt(ROSA)
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J), ROSA26+/Confetti (Gt(ROSA)26Sortm1(CAG-
Brainbow2.1)Cle/J) and Lyve1-eGFP-hCre knock-in mice (Lyve1Cre) mice were
acquired from The Jackson Laboratory (Bar Harbor, Maine) and housed in a
pathogen-free facility. Both females and males were used. All animal experiments
were carried out according to procedures approved by the St. Jude Children’s
Research Hospital Institutional Animal Care and Use Committee and comply with
all relevant ethical regulations regarding animal research.
Genotyping. Polymerase chain reactions (PCR) were performed using Go Taq
DNA Polymerase (Promega, Madison WI) as indicated by the manufacturer. PCR
conditions: (95 °C, 2’);((94 °C, 30”; 56 °C, 30”; 72 °C, 30”]×35); (72 °C, 10’).
Primers: Cre F1 (5’ CTGTTACGTATAGCCGAAAT 3’), Cre
R1 (5’ CTACACCAGAGACGGAAATC T 3’). CRE Positive PCR band: 203 bp.
Detection of the GFP allele was used for mTmG and Confetti allele genotyping:
GFP Fw (5’ CAGATGAAGCAGCACGACTTCT 3’), GFP Rv (5’ AACTCCAGC
AGGACCATGTGAT 3’). GFP PCR band: 400 bp.
Transplants. For all transplants, 8–12 weeks old CD45.2+/CD45.1+ C57BL/6 J
recipients were treated with 11 Gy of ionizing radiation in split doses of 5.5 Gy
prior to transplant. Males and females were used as recipients. In each experiment,
sexes of the recipient mice were evenly distributed among experimental groups. All
cells were transplanted by tail vein injection. E8.5, E9.5, E10.5, and E11.5 CD45.2+
Em-Ex-derived or YS-derived cells were transplanted along with 2 × 105 CD45.1+
C57BL/6.SJL WBM cells into recipients. For secondary and tertiary transplantation,
5 × 106, 2 × 106, 1 × 106, or 0.8 × 106 WBM cells were transplanted from primary or
secondary recipients. Engraftment was defined as >0.5% CD45.2+ cells in each
lineage (T cells, B cells, and myeloid cells) and >1% CD45.2+ total PB.
PB Analysis. PB was collected from the retro-orbital plexus in heparinized
capillary tubes (Fisherbrand, Pittsburgh, PA) and lysed in red blood cell lysis buffer
(Sigma-Aldrich, St. Louis, MO). Cells were stained with the following antibodies:
CD45.1-APC (A20) (Biolegend, San Diego, CA) or CD45.1-FITC (A20) (BD
Biosciences, San Diego, CA), B220-PECy7 and CD8-PECy7 (53–6.7) (Tonbo
Biosciences, San Diego, CA), CD45.2-V500 (104), B220- PerCPCy5.5 (RA3-6B2),
Gr1-PerCPCy5.5 (RB6-8C5), Cd11b-PerCPCy5.5 (M1/70) and CD4-PECy7 (RM4-
5) (BD Biosciences, San Diego, CA). All antibodies were used at 1:200 dilution.
4’,6-diamidino-2-phenylindole (DAPI) staining was used to gate live events.
Analysis was performed on a LSR Fortessa and a BD FACSAria III SORP (Special
Order Research Product, which contains the following LASERs: 405 nm, 445 nm,
488 nm, 562 nm, and 640 nm) (both BD Biosciences, San Diego, CA) and the data
analyzed with FlowJo version 9.4.11 (Tree Star, Ashland, OR). To discern the four
Confetti colors: the filter arrangements for each LASER were: CFP, 445 nm LASER
—470/24 band-pass filter (BP); GFP, 488 nm LASER—515/20 BP and 505 long-
Fig. 7 Blood precursors emerge from intra-embryonic LYVE1+ cells at the onset of the heartbeat. a Experimental schematic. YS and embryos dissected
from CD45.2+ E8.5 (5–7sp) Lyve1+/CreRosa26+/mTmG concepti were either analyzed by flow cytometry for Lyve1-Cre-dependent labeling (GFP+ cells),
cultured as explants for 10 days to examine Lyve1-Cre-dependent labeling in emerging hematopoietic populations or transplanted. b–g Flow cytometry
analysis and confocal microscopy of freshly isolated E8.5 (5–7sp) Lyve1+/CreRosa26mTmG YS and embryos. Non-recombined Rosa26+/mTmG cells are
tdTomato+ and recombined Rosa26+/mTmG cells are GFP+. b Representative flow cytometry plots. c Average % recombination (i.e., GFP+) of total YS or
embryo cells. (n= 14) from three independent litters. d % of total GFP+ cells expressing CD41. e %CD41+ in total cells. f % recombination (i.e., GFP+) in
CD41+ cells. g Representative confocal microscopy images. GFP (green), tdTomato (red). Endothelial cells (blue, labeled by anti-CD31-BV421). An inset
of a paired-aorta is shown. Scale bars: 50 µm and 10 µm. Schematics: A: paired-aorta; NT: Neural tube. h–i Flow cytometry analysis of E8.5 (5–7sp) Lyve1
+/CreRosa26mT/mG YS-Ex and Em-Ex after 10 days of culture. h Representative flow cytometry analysis of tdTomato and GFP labeling in YS-Ex and Em-Ex-
derived CD31+CD45+c-Kit+CD41− cells. I Quantification of Lyve1-Cre dependent GFP labeling in CD31+CD45+c-Kit+CD41− cells. Each dot represents an
independent conceptus. Bars represent average %recombination (n= 12) from three independent litters. j–l PB of recipients transplanted with cultured
E8.5 (5–7sp) or E9.5 (19–22sp) Lyve1+/CreRosa26mT/mG Em-Ex or YS-Ex. j Representative flow cytometry plots of recipient PB. tdTomato and GFP labeling
is shown. k % Explant-derived PB, estimated as the sum of the % of tdTomato+ and % of GFP+ cells in the PB. Each circle represents an independent
recipient. l %Lyve1-Cre dependent GFP labeling estimated as %GFP+ amongst % of Explant-derived PB cells is shown. Each circle represents an
independent mouse transplanted with four ee of E8.5 CD45.2+ Lyve1+/CreRosa26mTmG cultured Em-Ex (n= 4) in three independent experiments or one
ee of E9.5 CD45.2+ Lyve1+/CreRosa26mTmG cultured Em-Ex (n= 10) or YS-Ex (n= 6) in other three independent experiments. (*p < 0.05; ***p < 0.001;
eWrs-test). Means and standard deviations are shown. Source data are provided as a Source Data file
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pass filter (LP); YFP, 488 nm LASER—545/10 BP and 525 LP; RFP, 562 nm LASER
—610/20 BP and 600 LP48.
Explants cultures and flow cytometry analysis. Explant culture conditions
were adapted from the protocol developed by Medvinsky and colleagues29.
Embryo and YS-explants were cultured at the air-liquid interface on 0.65 μm DV
Durapore Membrane Filters (Merck Millipore, Cork, Ireland) in Iscove’s
Modified Dulbecco’s Medium-Glutamax (IMDM-Glutamax, Thermo Fisher
Scientific, Waltham, MA), 20% FCS (Lot #535905; Cat #FB-02; Omega Scientific,
Tarzana, CA), 0.1 mM 2-Mercaptoethanol (Thermo Fisher Scientific, Waltham,
MA), and 100 units/ml of Penicillin/Streptomycin (Thermo Fisher Scientific,
Waltham, MA) supplemented with recombinant murine SCF, recombinant murine
IL-3, and recombinant murine FLT3 Ligand (Peprotech, Rocky Hill, NJ, all at 100
ng/ml) (or with other cytokine combinations indicated along the text) for
9–10 days to allow engraftment from E8.5 tissues or for other time periods as
detailed in each figure. Membrane filters were sterilized and rinsed three times in
boiling water (five minutes/wash). Up to eight explants were carefully placed
on each membrane filter. Filters were then placed on in-house-made ring stands
(3.175 mm high; outside diameter: 32.3 mm; inside diameter: 23 mm; Teflon)
positioned in the well of a non-tissue-culture-treated 6-well-plate (Corning, NY,
USA) containing 2.25 mL of the above described culture media. Media was
not refreshed during the culture. Explants were recovered from filters using a
sterilized scalpel.
Freshly isolated embryonic tissues or cultured explants were dissociated with
collagenase (0.0012 g/ml, Sigma-Aldrich, St. Louis, MO) in Phosphate-Buffered
Saline (PBS, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% FCS
(Omega Scientific, Tarzana, CA). For flow cytometry cell sorting or analysis,
dissociated cells were stained with one or more of these antibodies: CD45.2-V500
(104) (BD Biosciences, San Diego, CA), CD41-PerCP-eFluor710 (eBioMWReg30)
(eBioscience, San Diego, CA), CD31-FITC (MEC13.3) (BD Biosciences, San Diego,
CA), c-Kit-APC-eFluor780 (2B8) (eBioscience, San Diego, CA), Lyve1-PE
(#223322) R&D Byosystems, Minneapolis, MN). All antibodies were used at 1:200
dilution. 4’,6-diamidino-2-phenylindole (DAPI) staining was used to gate live
events. Analysis was performed on a LSR Fortessa and cell sorting on a BD
FACSAria III SORP (Special Order Research Product) (both BD Biosciences, San
Diego, CA). Cells were collected employing the BD FACSDiva Software (version
8.0.1) (BD Biosciences, San Diego, CA). Data was analyzed with FlowJo version
9.4.11 (Tree Star, Ashland, OR).
Statistics and reproducibility. Summary statistics, including mean and
standard deviation, were reported for analyses. Two sample t or exact
Wilcoxon rank sum test were used to test for a difference between two groups
depending on the normality of the data, which was tested by the Shapiro-
Wilk test. False discovery rate (FDR) method developed by Benjamini and
Hochberg49 was used to correct for multiple comparisons at a level of 0.05.
Otherwise, p-values < 0.05 were considered statistically significant. Analyses
were conducted in R-3.3.1.
For limiting dilution analysis, parameters were estimated using a generalized
linear model with a complementary log-log link. The generalized Pearson Chi-
square was used to assess the goodness-of-fit to the model. The analyses were done
using program L-Calc and ELDA online software50.
All in vitro experiments were reliably reproduced at least 3 times with the
exception of Fig. 3Eii (the 5 days culture time point was n= 2) and Fig. 3Ei (within
the 5 days culture time point the SCF/IL3 and the SCF conditions were n= 2).
Sample size and number of experiment replicates are detailed in each Figure
Legend.
Single cell RNA-seq. Sorted YS-Ex-CD31+CD45+c-Kit+CD41− and Em-Ex-
CD31+CD45+c-Kit+CD41− were resuspended in PBS containing 0.04%BSA at a
concentration of 500–600 cells/ul. In total, 8600 cells per sample were loaded into
each well of a 10X Chromium single cell capture chip with a recovery of 3000–3500
cells per sample. The captured cells then underwent lysis, reverse transcription,
cDNA amplification, and library preparation with indexing per the manufacturer’s
protocol (10X Genomics). The libraries were sequenced together on an Illumina
Nextseq500 (Illumina Inc., San Diego, CA) using a high output 150 cycle kit with
read lengths recommended by 10X Genomics.
Single-cell RNAseq analysis. Raw data processing: Cellranger 2.0.151 was used to
process the raw fastq files and to generate unique molecular identifiers (UMI)
counts for each gene in each cell. The UMI count table was imported into R and
analyzed with Seurat 2.1.0 package52. The raw counts were normalized using
NormalizeData function with default parameters (normalization.method= Log-
Normalize). Cells expressing less than 1000 genes, more than 5000 genes or having
over 5% mitochondria reads were removed from the analysis to exclude potential
dead, broken or doublet cells. Bach effect is removed using R package scran v1.8.153
with k= 20, sigma= 0.1. To identify the X-cell population, R package Rtsne
v0.1354 was used to reduce data dimension to two for visualization with perplexity
= 20, initial_dims= 100. X-cell population was defined by clusters generated with
R package pdfCluster v1.0-255 and selected for further analysis. R package scmap
v1.1.556 was used to map single cells to cell clusters from Zhou et al.42 with
threshold= 0.7. In detail, R package scmap v1.1.5 computed the similarity between
expression profile of a single cell and centroid of cell clusters in the reference
data56. Cells were assigned to reference cell clusters with the highest similarity.
Multiple types of correlations (including Cosine similarity and Pearson and
Spearman correlations) were calculated and at least one of them had to be larger
than 0.7 (i.e., threshold= 0.7).
CFU assays. For analysis of CFU potential, 5–7sp embryos and YS were cultured
as explants at the air-liquid interface for five or 10 days in the same conditions
as indicated above (20% FCS, SCF, IL-3, FLT3L in IMDM). CD31+CD45+ and
CD31−CD45− cells were then isolated by FACS and plated in M3434 methylcel-
lulose (STEMCELL Technologies, Vancouver, Canada). Approximately
60,000 sorted cells were dispensed to 3 mL of M3434 and equally distributed into
two plates (#27150, STEMCELL Technologies, Vancouver, Canada). Colonies
were analyzed 10 days after plating.
Confocal microscopy. E8.5 concepti were isolated and fixed in 4% paraf-
ormaldehyde (Electron Microscopy Sciences, Hatfield, PA) overnight at 4 °C.
Concepti were then embedded in 4.5% low-melting-point agarose (Thermo Fisher
Scientific, Waltham, MA) and sectioned (100 μm slices) using a vibratome
(microtome with vibrating blade VT1200, Leica Byosystems Wetzlar, Germany).
Sections were washed three times with PBS 0.3% Triton X-100 (Biorad, Hercules,
CA) (30 min/wash) and permeabilized at 4 °C overnight in PBS 0.3% Triton X-100
(Biorad, Hercules, CA). Sections were then blocked in 0.3% Triton X-100 with 3%
donkey serum (Sigma-Aldrich, St. Louis, MO) in PBS at 4 °C overnight. Sections
were next incubated with previously conjugated anti-LYVE1 (Clone ALY7;
eBioscience. San Diego, CA), anti-CD41 (Clone MWReg30; BD Bioscience, San
Diego, CA), BV421−Rat Anti-Mouse CD31 (Clone MEC 13.3 (RUO); BD Bios-
ciences, San Diego, CA) at 1:200 in 1% skimmed milk in 0.3% Triton X-100-PBS
overnight. Anti-LYVE1 and anti-CD41 antibodies were conjugated following
manufacture’s protocol to CFTM568 and CFTM488 fluorophores, respectively,
using the Mix-n-StainTM labeling kits (Sigma-Aldrich, St. Louis, MO). Sections
were then washed three times with 0.3% Triton X-100 in PBS (30 min/wash).
Sections were mounted on Fisherbrand Superfrost Microscope Slides (Fisher Sci-
entific, Pittsburgh, PA) and covered with 22 × 22 mm No.1.0 microscope cover
glass (Infolab, Indianapolis, IN). Sections were imaged on a Zeiss LSM780 Confocal
Microscope (Zeiss, Oberkochen, Germany) using a ×40, 1.1NA water immersion
lens. Images were processed employing a ZEN 2012 software (Zeiss, Oberkochen,
Germany).
Data availability
The authors declare that all data supporting the findings of this study are
available within the article and its supplementary information files or from the
corresponding author upon reasonable request. Single-cell RNAseq data
have been deposited in NCBI’s Gene Expression Omnibus (GEO) database
under accession code GSE110909. The source data underlying Figs. 1, 2, 3, 4A, 5,
6A-C and 7 and Supplementary Figs. 1A, and 3 are provided as a Source Data file.
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